FY2029 EPS Estimates for Immunome Raised by HC Wainwright

Immunome, Inc. (NASDAQ:IMNM) – HC Wainwright upped their FY2029 earnings per share (EPS) estimates for shares of Immunome in a report issued on Wednesday, March 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of $0.69 per share for the year, up from their prior estimate of $0.63. HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Immunome’s FY2030 earnings at $1.35 EPS.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%.

A number of other equities research analysts also recently weighed in on IMNM. Truist Financial began coverage on Immunome in a report on Monday, December 1st. They issued a “buy” rating and a $36.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a research note on Thursday, January 15th. Craig Hallum boosted their target price on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. Guggenheim raised their price target on shares of Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Stephens decreased their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immunome has an average rating of “Moderate Buy” and an average price target of $32.33.

Immunome Trading Down 7.0%

IMNM stock opened at $20.95 on Thursday. The firm has a market cap of $2.31 billion, a PE ratio of -8.66 and a beta of 2.12. The stock has a 50-day moving average price of $22.75 and a 200-day moving average price of $17.60. Immunome has a 1-year low of $5.15 and a 1-year high of $27.65.

Insider Activity

In other Immunome news, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the transaction, the director owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Philip Tsai bought 10,000 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was acquired at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the purchase, the insider directly owned 43,300 shares in the company, valued at approximately $887,217. The trade was a 30.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 68,518 shares of company stock worth $1,453,958 over the last quarter. Insiders own 7.69% of the company’s stock.

Institutional Trading of Immunome

A number of hedge funds have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. grew its stake in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares during the period. Vanguard Group Inc. raised its stake in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the period. Primecap Management Co. CA boosted its holdings in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after buying an additional 1,667,432 shares during the last quarter. State Street Corp boosted its holdings in shares of Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after buying an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after buying an additional 2,823,144 shares during the period. 44.58% of the stock is currently owned by institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.